Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: primary results of a placebo- and active-controlled phase 2b dose-finding study

被引：0
|
作者：
Maurer, M. [1 ]
Gimenez-Arnau, A. [2 ]
Sussman, G. [3 ]
Loeffler, J. [4 ]
Barve, A. [5 ]
Severin, T. [4 ]
Janocha, R. [4 ]
机构：
[1] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Autonoma Barcelona, Hosp del Mar, Dermatol Dept, Barcelona, Spain
[3] Univ Toronto, Div Allergy & Clin Immunol, Toronto, ON, Canada
[4] Novartis Pharma AG, Basel, Switzerland
[5] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P110
引用
收藏
页码：121 / 121
页数：1
相关论文
共 22 条
  • [1] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: Primary results of a placebo- and active-controlled phase 2b dose finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    ALLERGY, 2018, 73 : 837 - 837
  • [2] Ligelizumab as add-on therapy for patients with anti-H1-refractory CSU: Primary results of a placebo- and active-controlled phase 2b dose-finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Manetsch, M.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    SWISS MEDICAL WEEKLY, 2021, 151 : 22S - 22S
  • [3] A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
    Saini, Sarbjit
    Rosen, Karin E.
    Hsieh, Hsin-Ju
    Wong, Dennis A.
    Conner, Edward
    Kaplan, Allen
    Spector, Sheldon
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (03) : 567 - U195
  • [4] LIGELIZUMAB REDUCES RESCUE MEDICATION USE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
    Sitz, K.
    Soong, W.
    Lanier, B.
    Kobayashi, K.
    Barve, A.
    Hua, E.
    Janocha, R.
    Severin, T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S28 - S28
  • [5] EFFICACY AND SAFETY OF OMALIZUMAB IN H1-ANTIHISTAMINE-REFRACTORY CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA: RESULTS OF A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Saini, S. S.
    Bindslev-Jensen, C.
    Maurer, M.
    Grob, J. J.
    Baskan, E. Bulbul
    Bradley, M. S.
    Georgiou, P.
    Alpan, O.
    Spector, S.
    Rosen, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A18 - A18
  • [6] Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial
    Leducq, Sophie
    Samimi, Mahtab
    Bernier, Claire
    Soria, Angele
    Amsler, Emmanuelle
    Staumont-Salle, Delphine
    Gabison, Germaine
    Chosidow, Olivier
    Beneton, Nathalie
    Bara, Corina
    Grange-Prunier, Anne
    Wierzbicka-Hainaut, Ewa
    Brenaut, Emilie
    Droitcourt, Catherine
    Raison-Peyron, Nathalie
    Bourgoin, Helene
    Cornillier, Helene
    Machet, Laurent
    Giraudeau, Bruno
    Caille, Agnes
    Maruani, Annabel
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (01) : 240 - 243
  • [7] Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
    Savitz, Adam
    Wajs, Ewa
    Zhang, Yun
    Xu, Haiyan
    Etropolski, Mila
    Thase, Michael E.
    Drevets, Wayne C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2021, 24 (12): : 965 - 976
  • [8] Efficacy and Safety of Seltorexant as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Phase 2b, Randomized, Placebo-Controlled, Parallel-Group, Adaptive Dose-Finding Study
    Savitz, Adam
    Wajs, Ewa
    Zhang, Yun
    Xu, Haiyan
    Etropolski, Mila
    Saoud, Jay
    Luthringer, Remy
    Drevets, Wayne
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 123 - 123
  • [9] Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study
    Yamaguchi, Yuji
    Peeva, Elena
    Adiri, Roni
    Ghosh, Pranab
    Napatalung, Lynne
    Hamzavi, Iltefat
    Pandya, Amit G.
    Shore, Ronald N.
    Ezzedine, Khaled
    Guttman-Yassky, Emma
    Shore, Ronald N.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (04) : 781 - 789
  • [10] Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase b Study
    Lu, Qianjin
    Yang, Bin
    Liu, Lunfei
    Li, Linfeng
    Liu, Weijun
    Yao, Xu
    Man, Xiaoyong
    Chen, Aijun
    Shi, Yuling
    Ding, Yangfeng
    Sun, Qing
    Tao, Juan
    Liang, Chris
    Liu, Yong
    Liu, Donghua
    Sun, Peiyu
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB372 - AB372
123